RELATED PARTY TRANSACTION (Details Narrative) - USD ($) |
3 Months Ended | ||||
---|---|---|---|---|---|
Sep. 30, 2023 |
Mar. 31, 2025 |
Mar. 31, 2024 |
Dec. 31, 2024 |
Aug. 12, 2024 |
|
Proceeds from common stock | $ 0 | $ 500,000 | |||
Investment | 6,941,083 | $ 5,691,084 | |||
Other Investments | 6,941,083 | 5,691,084 | |||
AG Bio Life Capital I LP [Member] | |||||
Shares issued | 600,000 | ||||
Proceeds from common stock | $ 100,000 | ||||
Note receivable | $ 522,667 | ||||
Investment | $ 522,667 | $ 522,667 |
X | ||||||||||
- Definition Amount, after allowance for credit loss, of accounts and financing receivable. Includes, but is not limited to, notes and loan receivable. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition Sum of the carrying amounts as of the balance sheet date of all investments. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
X | ||||||||||
- Definition Amount of investments classified as other. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition The cash inflow from the additional capital contribution to the entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Number of shares of stock issued attributable to transactions classified as other. No definition available.
|
X | ||||||||||
- Details
|